


Randomised Trial of Cryo ablation versus Cardioversion in Persistent Atrial Fibrillation (CHILLY-AF)

Results

Trial registration number: <https://doi.org/10.1186/ISRCTN38385178>



	DCCV			Cryo ablation			Overall		
	Median	IQR	n	Median	IQR	n	Median	IQR	n
Age (years)	65.0	58.9 to 71.4	74	64.5	58.8 to 72.3	75	64.8	58.8 to 71.4	149
Weight (kg)	89.5	79.0 to 103.0	74	98.5	87.0 to 108.0	74	95.0	82.5 to 106.0	148
Height (cm)	175.0	169.0 to 181.0	73	177.0	170.0 to 183.0	73	176.0	169.0 to 182.0	146
BMI (kg/m ²)	30.1	27.1 to 33.3	73	30.8	27.3 to 35.0	72	30.4	27.1 to 34.0	145
	No.	%		No.	%		No.	%	
Gender									
Male	48	64.9		58	77.3		106	71.1	
Female	26	35.1		17	22.7		43	28.9	
Total	74	100.0		75	100.0		149	100.0	
Ethnicity									
White	74	100.0		74	98.7		148	99.3	
Asian / Asian British	0	0.0		1	1.3		1	0.7	
Total	74	100.0		75	100.0		149	100.0	

Primary outcome analysis

AF recurrence (between 30 and 379 days after intervention) and time to recurrence by group and overall.

	DCCV			Cryo ablation			Overall		
	No.	%		No.	%		No.	%	
Recurrence between 30 and 379 days after intervention									
No	26	36.1		36	48.0		62	42.2	
Yes	46	63.9		39	52.0		85	57.8	
Total	72	100.0		75	100.0		147	100.0	
	Median	IQR	n	Median	IQR	n	Median	IQR	n
Time to AF recurrence (days)	45.5	34.0 to 115.0	46	84.0	33.0 to 192.0	39	54.0	34.0 to 142.0	85

Secondary outcome analyses

Safety endpoint: Composite of death from any cause and serious adverse events

Summary of AE seriousness by group and overall.

	DCCV		Cryo ablation		Overall	
	No.	%	No.	%	No.	%
AE or SAE/death						
Non-serious AE	36	64.3	37	62.7	73	63.5
SAE or death	20	35.7	22	37.3	42	36.5
Total	56	100.0	59	100.0	115	100.0